| 2.55 0.04 (1.59%) | 09-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.77 | 1-year : | 4.4 |
| Resists | First : | 3.23 | Second : | 3.77 |
| Pivot price | 2.48  |
|||
| Supports | First : | 1.32 | Second : | 0.14 |
| MAs | MA(5) : | 2.58  |
MA(20) : | 1.91 |
| MA(100) : | 0.61 |
MA(250) : | 0.77 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 78 |
D(3) : | 78.8 |
| RSI | RSI(14): 75.3 |
|||
| 52-week | High : | 3.23 | Low : | 0.14 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ BRTX ] has closed below upper band by 47.4%. Bollinger Bands are 257.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 13 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.68 - 2.7 | 2.7 - 2.71 |
| Low: | 2.37 - 2.39 | 2.39 - 2.4 |
| Close: | 2.53 - 2.55 | 2.55 - 2.57 |
BioRestorative Therapies, Inc. is a life sciences company dedicated to developing regenerative medicine products and therapies. Their approach primarily utilizes adult stem cell protocols to address two key areas: disc/spine disease and metabolic disorders. Within their disc/spine program, known as brtxDisc, the company's leading cell therapy candidate is BRTX-100. This treatment involves culturing mesenchymal stem cells harvested from a patient's own bone marrow (autologous) to provide a non-surgical solution for painful lumbosacral disc conditions. BRTX-100 has successfully completed Phase 1 clinical trials. The company is also advancing its Metabolic Program, named ThermoStem, which is currently in the preclinical stage. This cell-based therapy targets obesity and other metabolic ailments by employing brown adipose-derived stem cells to generate brown adipose tissue. Beyond these core programs, BioRestorative Therapies also offers an investigational curved needle device designed for delivering cells and various therapeutic materials to the spine and discs. The company fosters strategic research and development partnerships, including agreements with Rohto Pharmaceutical Co., Ltd., Pfizer, Inc., and the University of Pennsylvania. Founded in 1997 and headquartered in Melville, New York, the company was initially known as Stem Cell Assurance, Inc., before rebranding to BioRestorative Therapies, Inc. in August 2011.
Thu, 03 Sep 2026
BioRestorative Therapies Announces Reverse Stock Split - Ortho Spine News
Fri, 14 Aug 2026
BioRestorative Therapies (BRTX) delays Q2 10-Q amid losses and going-concern risk - Stock Titan
Thu, 23 Jul 2026
BioRestorative Therapies (BRTX) Slides 1.58% as Stock Nears Critical Support Zone - Conversion Trade - careplusvn.com
Thu, 25 Jun 2026
BioRestorative Therapies Announces Completion of BRTX-100 Manufacturing for Phase 2 Clinical Trial - Quiver Quantitative
Wed, 27 May 2026
BioRestorative Therapies stock surges on activist stake - Investing.com
Tue, 26 May 2026
Stem cell back pain shot finishes Phase 2, topline data due 2027 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 28 (M) |
| Held by Insiders | 2.418e+007 (%) |
| Held by Institutions | 9.5 (%) |
| Shares Short | 39 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.401e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -14 % |
| Return on Assets (ttm) | 612.5 % |
| Return on Equity (ttm) | -118.9 % |
| Qtrly Rev. Growth | 357870 % |
| Gross Profit (p.s.) | -9.87 |
| Sales Per Share | -325.87 |
| EBITDA (p.s.) | 445338 |
| Qtrly Earnings Growth | -21.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 15.72 |
| Dividend | 0 |
| Forward Dividend | 4980 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|